Bank of New York Mellon Corp Acquires 35,760 Shares of Evolus, Inc. (NASDAQ:EOLS)

Bank of New York Mellon Corp lifted its holdings in Evolus, Inc. (NASDAQ:EOLS) by 24.6% in the second quarter, according to the company in its most recent filing with the SEC. The fund owned 181,093 shares of the company’s stock after acquiring an additional 35,760 shares during the quarter. Bank of New York Mellon Corp owned 0.29% of Evolus worth $1,965,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in EOLS. BNP Paribas Financial Markets grew its holdings in shares of Evolus by 137.4% in the fourth quarter. BNP Paribas Financial Markets now owns 220,399 shares of the company’s stock worth $2,321,000 after purchasing an additional 127,541 shares during the last quarter. Dynamic Technology Lab Private Ltd bought a new stake in Evolus in the 4th quarter worth $191,000. Trexquant Investment LP grew its holdings in Evolus by 74.9% in the 4th quarter. Trexquant Investment LP now owns 158,075 shares of the company’s stock worth $1,665,000 after acquiring an additional 67,678 shares during the last quarter. Aigen Investment Management LP increased its position in shares of Evolus by 72.0% in the fourth quarter. Aigen Investment Management LP now owns 51,221 shares of the company’s stock valued at $539,000 after acquiring an additional 21,438 shares during the period. Finally, Tradition Wealth Management LLC raised its stake in shares of Evolus by 44.8% during the fourth quarter. Tradition Wealth Management LLC now owns 8,000 shares of the company’s stock valued at $84,000 after acquiring an additional 2,475 shares during the last quarter. Hedge funds and other institutional investors own 90.69% of the company’s stock.

Insider Buying and Selling at Evolus

In other news, CMO Tomoko Yamagishi-Dressler sold 5,631 shares of the business’s stock in a transaction on Friday, August 30th. The shares were sold at an average price of $15.85, for a total value of $89,251.35. Following the transaction, the chief marketing officer now owns 82,375 shares of the company’s stock, valued at $1,305,643.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other Evolus news, CFO Sandra Beaver sold 3,276 shares of the company’s stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $14.98, for a total transaction of $49,074.48. Following the sale, the chief financial officer now directly owns 148,502 shares in the company, valued at $2,224,559.96. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CMO Tomoko Yamagishi-Dressler sold 5,631 shares of Evolus stock in a transaction on Friday, August 30th. The stock was sold at an average price of $15.85, for a total transaction of $89,251.35. Following the transaction, the chief marketing officer now directly owns 82,375 shares of the company’s stock, valued at $1,305,643.75. The disclosure for this sale can be found here. Insiders own 6.10% of the company’s stock.

Wall Street Analysts Forecast Growth

EOLS has been the subject of several research reports. Cantor Fitzgerald restated an “overweight” rating on shares of Evolus in a report on Monday. HC Wainwright reissued a “buy” rating and issued a $27.00 price target on shares of Evolus in a research note on Thursday, August 1st. Needham & Company LLC restated a “buy” rating and issued a $22.00 price objective on shares of Evolus in a report on Friday, September 13th. Finally, Barclays upped their target price on Evolus from $16.00 to $20.00 and gave the stock an “overweight” rating in a report on Friday, September 13th.

Evolus Stock Up 0.7 %

Evolus stock opened at $16.89 on Wednesday. Evolus, Inc. has a one year low of $7.44 and a one year high of $17.70. The stock has a fifty day moving average of $13.87 and a 200 day moving average of $13.06. The company has a debt-to-equity ratio of 6.26, a quick ratio of 2.67 and a current ratio of 2.92. The stock has a market cap of $1.06 billion, a PE ratio of -15.97 and a beta of 1.30.

Evolus (NASDAQ:EOLS) last posted its quarterly earnings data on Wednesday, July 31st. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.02). The firm had revenue of $66.91 million during the quarter, compared to analysts’ expectations of $65.06 million. As a group, sell-side analysts predict that Evolus, Inc. will post -0.64 EPS for the current year.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.